LEGN vs LQDA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LEGN exhibits severe financial instability as evidenced by a critical Piotroski F-Score of 1/9, indicating poor operational health. While the company shows impressive top-line revenue growth of 64.20%, this is offset by consistent earnings misses (average surprise of -66.26% over the last 4 quarters) and a devastating technical trend (0/100). There is a stark disconnect between the bullish analyst target of $57.22 and the actual price performance, which has declined over 41% in the last year. The stock currently behaves as a high-risk speculative asset with failing fundamental health markers.
Liquidia Corporation presents a high-risk, high-reward profile characterized by a critical Piotroski F-Score of 1/9, indicating severe fundamental weakness. While the company has achieved explosive revenue growth (3054.60% YoY) and maintains a strong gross margin of 91.64%, its balance sheet is distressed with a Debt/Equity ratio of 4.42 and an ROE of -111.05%. The market is pricing in significant future success, as evidenced by a Price/Book ratio of 75.73, though insider selling and a bearish technical trend suggest a potential near-term peak. The disconnect between analyst optimism (Buy rating) and deterministic health scores necessitates a neutral stance.
Compare Another Pair
Related Comparisons
LEGN vs LQDA: Head-to-Head Comparison
This page compares Legend Biotech Corporation (LEGN) and Liquidia Corporation (LQDA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.